# Addpharma Inc. clinical trials: 58 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 58 trials with Addpharma Inc. as lead sponsor, 24 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Addpharma Inc.: 58 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/addpharma-inc

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 58
- Recruiting or not yet: 24
- Read on: November 19, 2026

## Trials

The 25 newest of 58, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| September 11, 2026 | NCT07816198 | A Study to Evaluate the Efficacy and Safety of AD-233A, AD-233B, AD-233C and/or AD-233D Combination Therapy | Addpharma Inc. | Phase 3 | Not yet recruiting | Type 2 Diabetes Mellitus (T2DM) | 354 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07816198) |
| July 28, 2026 | NCT07730567 | A Study to Evaluate the Pharmacokinetic Interaction and the Safety of AD-236A and AD-236B | Addpharma Inc. | Phase 1 | Not yet recruiting | Hyperlipidemia, Diabete Type 2 | 44 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07730567) |
| July 23, 2026 | NCT07722871 | A Clinical Trial to Evaluate the Bioequivalence of AD-116A and AD-1161 Under Fed Conditions in Healthy Adult Male Volunteers | Addpharma Inc. | Phase 1 | Not yet recruiting | Benign Prostatic Hyperplasia | 44 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07722871) |
| July 21, 2026 | NCT07717775 | A Study of Compare the Pharmacokinetic, Pharmacodynamic and Safety/Tolerability Characteristics Following Multiple Oral Administration of... | Addpharma Inc. | Phase 1 | Not yet recruiting | Gastritis | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07717775) |
| July 21, 2026 | NCT07717749 | A Study to Evaluate the Safety, Pharmacokinetics of AD-118 and AD-1181 in Healthy Adult Subjects | Addpharma Inc. | Phase 1 | Not yet recruiting | Chronic Heart Failure | 74 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07717749) |
| July 20, 2026 | NCT07715305 | A Clinical Trial to Evaluate the Bioequivalence of AD-116A Compared to AD-1161 in Healthy Adult Male Volunteers | Addpharma Inc. | Phase 1 | Not yet recruiting | Benign Prostatic Hyperplasia | 44 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07715305) |
| June 1, 2026 | NCT07618845 | A Clinical Trial to Assess the Pharmacokinetics, Safety, and Food Effect of AD-230 in Healthy Adults | Addpharma Inc. | Phase 1 | Not yet recruiting | Chronic Liver Disease (CLD) | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07618845) |
| May 15, 2026 | NCT07590167 | A Study to Evaluate the Safety and Pharmacokinetics of AD-231 Compared to Coadministration of AD-231A, AD-231D and AD-231C | Addpharma Inc. | Phase 1 | Not yet recruiting | Dyslipidemia, Hypertension | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07590167) |
| April 24, 2026 | NCT07550231 | Determining the Optimal Dose of AD-211 in Patients With Osteoarthritis of the Knee | Addpharma Inc. | Phase 2 | Not yet recruiting | Osteoarthritis of the Knees | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07550231) |
| April 20, 2026 | NCT07538466 | A Study to Evaluate the Safety and Pharmacokinetics of AD-123 Compared to Coadministration of AD-1231 and AD-1232 | Addpharma Inc. | Phase 1 | Not yet recruiting | Diabetes Mellitus | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07538466) |
| April 9, 2026 | NCT07521241 | A Clinical Trial to Evaluate the Pharmacokinetics and Safety of AD-230 in Healthy Adults | Addpharma Inc. | Phase 1 | Not yet recruiting | Chronic Liver Disease (CLD) | 52 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07521241) |
| March 27, 2026 | NCT07495514 | A Study to Evaluate the Effect of Food on the Pharmacokinetic Characteristics and Safety Profile of AD-117 in Healthy Adult Volunteers | Addpharma Inc. | Phase 1 | Completed | Mixed Dyslipidemia, Food Effect Study of AD-117 | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07495514) |
| March 17, 2026 | NCT07476157 | A Study to Evaluate the Safety and Pharmacokinetics of AD-118 and AD-1181 in Healthy Adult Subjects | Addpharma Inc. | Phase 1 | Not yet recruiting | Chronic Heart Failure | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07476157) |
| March 2, 2026 | NCT07444385 | A Study to Evaluate the Safety and Pharmacokinetics of AD-116 and AD-1161 in Healthy Adult Male Subjects | Addpharma Inc. | Phase 1 | Recruiting | Benign Prostatic Hyperplasia | 44 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07444385) |
| February 4, 2026 | NCT07385248 | A Clinical Trial to Assess the Pharmacokinetics and Safety of AD-229 Compared to AD-2291 in Healthy Adults | Addpharma Inc. | Phase 1 | Not yet recruiting | Gastritis | 28 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07385248) |
| February 4, 2026 | NCT07385235 | Compare and Evaluate the Safety and PK Data of a Single Dose Administration of 'AD-115A' or 'AD-1151' | Addpharma Inc. | Phase 1 | Recruiting | Gastric Ulcer | 46 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07385235) |
| December 31, 2025 | NCT07312799 | Evaluate the Pharmacokinetic Interaction and the Safety of AD-2321 and AD-2322 | Addpharma Inc. | Phase 1 | Not yet recruiting | Hypertension | 41 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07312799) |
| December 31, 2025 | NCT07312773 | A Study to Evaluate the Pharmacokinetic Interaction and the Safety of AD-231A and AD-231B and AD-231C | Addpharma Inc. | Phase 1 | Not yet recruiting | Hypertension, Hyperlipidemia | 55 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07312773) |
| September 3, 2025 | NCT07152873 | A Study to Compare to PK Characteristics and Safety Profiles Between AD-117 and AD-117A | Addpharma Inc. | Phase 1 | Not yet recruiting | Mixed Dyslipidemia | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07152873) |
| August 5, 2025 | NCT07103278 | A Clinical Trial to Evaluate the Safety and the Pharmacokinetics of AD-116 Compared to AD-1161 in Healthy Adult Male Volunteers | Addpharma Inc. | Phase 1 | Completed | Benign Prostatic Hyperplasia | 44 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07103278) |
| May 16, 2025 | NCT06976489 | The Food Effect on PK Characteristics and Safety Profiles of PA-111 | Addpharma Inc. | Phase 1 | Not yet recruiting | Mixed Dyslipidemia | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06976489) |
| April 17, 2025 | NCT06932705 | A Study to Compare to PK Characteristics and Safety Profiles Between PA-111 and PA-111A | Addpharma Inc. | Phase 1 | Recruiting | Mixed Dyslipidemia | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06932705) |
| April 8, 2025 | NCT06916130 | A Study to Compare PK/PD Characteristics and Safety Profiles Between AD-120 and AD-120A | Addpharma Inc. | Phase 1 | Not yet recruiting | Gastroesophageal Reflux Disease (GERD) | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06916130) |
| March 30, 2025 | NCT06902818 | The Study Compare and Evaluate the Safety and PK Data of a Single Dose Administration of 'AD-115A' or 'AD-1151' | Addpharma Inc. | Phase 1 | Completed | Gastric Ulcer | 46 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06902818) |
| March 19, 2025 | NCT06884098 | A Study to Compare PK Characteristics and Safety Profiles Between AD-228B and AD-2284 | Addpharma Inc. | Phase 1 | Recruiting | Primary Hypercholesterolaemia | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06884098) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 42 |
| Phase 2 | 3 |
| Phase 3 | 13 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 33 |
| Not yet recruiting | 18 |
| Recruiting | 6 |
| Unknown | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Essential Hypertension | 8 |
| Hypertension | 8 |
| Hyperlipidemias | 6 |
| Gastroesophageal Reflux | 5 |
| Prostatic Hyperplasia | 4 |
| Gastritis | 3 |
| Alopecia | 2 |
| Osteoporosis | 2 |
| Stomach Ulcer | 2 |
| Hypercholesterolemia | 2 |
| Diabetes Mellitus, Type 2 | 2 |
| Dyslipidemias | 1 |
| Embolism and Thrombosis | 1 |
| Diabetes Mellitus | 1 |
| Pain | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Fish and chips restaurants in the United States](https://specstream.ai/data/businesses/fish-and-chips-restaurants/united-states)
- [Chicken wings restaurants in the United States](https://specstream.ai/data/businesses/chicken-wings-restaurants/united-states)
- [Agricultural services in the United States](https://specstream.ai/data/businesses/agricultural-services/united-states)
- [Shutters companies in the United States](https://specstream.ai/data/businesses/shutters-companies/united-states)
- [Obstetrics and gynecology practices in the United States](https://specstream.ai/data/businesses/obstetrics-and-gynecology-practices/united-states)
- [Home insurance agencies in the United States](https://specstream.ai/data/businesses/home-insurance-agencies/united-states)
